Angiodysplasia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Nikita Singh (talk | contribs) |
Nikita Singh (talk | contribs) |
||
| Line 15: | Line 15: | ||
* Endoscopic techniques are the therapy of choice for angiodysplasia. | * Endoscopic techniques are the therapy of choice for angiodysplasia. | ||
* Argon plasma coagulation (APC): Most widely used endoscopic method for the treatment of angiodysplasia that uses high frequency electric current and ionised argon gas. | * Argon plasma coagulation (APC): Most widely used endoscopic method for the treatment of angiodysplasia that uses high frequency electric current and ionised argon gas.<ref name="pmid14722558">{{cite journal| author=Vargo JJ| title=Clinical applications of the argon plasma coagulator. | journal=Gastrointest Endosc | year= 2004 | volume= 59 | issue= 1 | pages= 81-8 | pmid=14722558 | doi=10.1016/s0016-5107(03)02296-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14722558 }} </ref> | ||
==References== | ==References== | ||
Revision as of 05:28, 15 October 2021
|
Angiodysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiodysplasia medical therapy On the Web |
|
American Roentgen Ray Society Images of Angiodysplasia medical therapy |
|
Risk calculators and risk factors for Angiodysplasia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikita Singh, M.D.[2]
Overview
Treatment is not required for incidentally found, asymptomatic, non-bleeding lesions. However, it is considered for non-bleeding angiodysplasia with symptoms of occult or overt GI bleed. The invasiveness of therapy depends on clinical severity of anemia, hemodynamic stability and recurrence of symptoms. Although endoscopic techniques are the first choice, hormonal therapy, thalidomide and octreotide are the pharmacological options that have been tried for patients with significant co-morbidities who cannot undergo invasive procedures.
Medical Therapy
- Pharmacological options like hormonal therapy, thalidomide, and octreotide have been tried in patients with significant co-morbidities who cannot undergo invasive procedures.
- Studies have shown hormonal therapy with ethinylestradiol and norethisterone vs placebo have no difference in outcomes.[1] However, a few case series have shown positive results regarding the efficacy of hormonal therapy in chronic renal failure patients.[2]
- Thalidomide inhibits angiogenesis by inhibiting vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis.[3] It has been reported to be effective in the management of chronic bleeding from angiodysplasia as well as reduction in the number and size of lesions in numerous.[4][5][6][7]
- Long-acting octreotide has been used to treat chronic bleeding due to angiodysplasia in elderly patients.[8]
Endoscopic Therapy
- Endoscopic techniques are the therapy of choice for angiodysplasia.
- Argon plasma coagulation (APC): Most widely used endoscopic method for the treatment of angiodysplasia that uses high frequency electric current and ionised argon gas.[9]
References
- ↑ Junquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM; et al. (2001). "A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia". Gastroenterology. 121 (5): 1073–9. doi:10.1053/gast.2001.28650. PMID 11677198.
- ↑ Bronner MH, Pate MB, Cunningham JT, Marsh WH (1986). "Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial". Ann Intern Med. 105 (3): 371–4. doi:10.7326/0003-4819-105-3-371. PMID 3488703.
- ↑ Chen HM, Ge ZZ, Liu WZ, Lu H, Xu CH, Fang JY; et al. (2009). "[The mechanisms of thalidomide in treatment of angiodysplasia due to hypoxia]". Zhonghua Nei Ke Za Zhi. 48 (4): 295–8. PMID 19576118.
- ↑ Heidt J, Langers AM, van der Meer FJ, Brouwer RE (2006). "Thalidomide as treatment for digestive tract angiodysplasias". Neth J Med. 64 (11): 425–8. PMID 17179574.
- ↑ Almadi M, Ghali PM, Constantin A, Galipeau J, Szilagyi A (2009). "Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review". Can J Gastroenterol. 23 (9): 625–31. doi:10.1155/2009/862816. PMC 2776553. PMID 19816627.
- ↑ Kamalaporn P, Saravanan R, Cirocco M, May G, Kortan P, Kandel G; et al. (2009). "Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series". Eur J Gastroenterol Hepatol. 21 (12): 1347–50. doi:10.1097/MEG.0b013e32832c9346. PMID 19730385.
- ↑ Bauditz J, Lochs H, Voderholzer W (2006). "Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide". Endoscopy. 38 (10): 1036–9. doi:10.1055/s-2006-944829. PMID 17058171.
- ↑ Orsi P, Guatti-Zuliani C, Okolicsanyi L (2001). "Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract". Dig Liver Dis. 33 (4): 330–4. doi:10.1016/s1590-8658(01)80087-6. PMID 11432511.
- ↑ Vargo JJ (2004). "Clinical applications of the argon plasma coagulator". Gastrointest Endosc. 59 (1): 81–8. doi:10.1016/s0016-5107(03)02296-x. PMID 14722558.